Navigation Links
GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update
Date:11/15/2007

Sep. 30, Dec. 31

2007 2006

Assets:

Cash and cash equivalents $732 $2,088

Other current assets 24 38

Total current assets 756 2,126

Property and other assets 228 270

Total assets $984 $2,396

Liabilities and stockholders'

equity

Current liabilities $683 $193

Stockholders' equity (deficit) 301 2,203

Total liabilities and stockholders' equity $984 $2,396

Shares Outstanding 712,835 711,168

About GeoVax Labs, Inc.

GeoVax Inc. is an Atlanta, Georgia USA biotechnology company, established to develop, manufacture, license and commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents. GeoVax's vaccine technology is protected by 20 issued and filed patent applications.

GeoVax's DNA and Recombinant MVA HIV/AIDS vaccines:

-- Protected 22 of 23 (96%) non-human primates for over 3 1/2 years post-

infection with an AIDS causing virus - 5 of 6 non-vaccinates controls

died of AIDS

-- Are manufactured and tested under GMP/GLP - EMEA (EU) and FDA

guidelines

-- Satisfactorily completed early Phase 1 human clinical trial for DNA

HIV/AIDS vaccine

-- Are currently in 2 ongoing human trials started in 2006 with positive

immune responses reported in the majority of vaccine recipients as well

as good vaccine safety

-- Began 2 additional human trials in June 2007 with a large Phase 2 trial

in planning for 2008

For more information visit

SOURCE GeoVax Labs, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
2. GeoVax Labs, Inc. Comments on Discontinuance of Mercks HIV Vaccine Trial
3. Excellent Results Received from GeoVaxs Full-Dose HIV/AIDS Vaccine Trial
4. Biopure Announces 2007 Third Quarter Financial Results
5. Gen-Probe Announces Webcast of Third Quarter 2007 Earnings Conference Call
6. The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
7. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
8. QIAGEN N.V. (Nasdaq: QGEN) Invites You to Join Its Third Quarter 2007 Earnings Conference Call on the Web
9. Pharmacopeia Announces Third Quarter 2007 Financial Results
10. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
11. PharmAthene to Webcast its Third Quarter Conference Call on November 13, 2007 at 4:30 P.M. Eastern Time
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... May 4, 2015 MEI Pharma, Inc. ... on the clinical development of novel therapies for ... effects of the Company,s investigational drug candidate ME-344 ... when combined with a tyrosine-kinase inhibitor (TKI). In ... be a potent inhibitor of mitochondrial oxidative phosphorylation ...
(Date:5/4/2015)... 4, 2015  Geneia, a company of experienced ... to improve healthcare efficiencies, today announced a first-of-its-kind ... (BNRC) use Geneia,s advanced analytics solution coupled ... quality and lower the cost of patient care. ... claims and utilization data from multiple sources to ...
(Date:5/4/2015)... 2015 Intarcia Therapeutics, Inc. ... into the newly created role of Chief ... pharmaceutical executive with world-class experience – most recently ... service at industry leaders such as Pfizer and ... range of therapeutic areas, including: cardiovascular, metabolic, oncology, ...
Breaking Medicine Technology:MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 2MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 3MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 4MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 5Geneia Launches First-of-its-Kind Partnership to Use Advanced Analytics to Improve the Quality and Cost of Care for Skilled Nursing and Rehabilitation Patients 2Geneia Launches First-of-its-Kind Partnership to Use Advanced Analytics to Improve the Quality and Cost of Care for Skilled Nursing and Rehabilitation Patients 3Intarcia Names Top Commercial Expert Michael Williams As COO; Will Chair Commercial Committee And Lead ITCA 650 Launch In U.S. 2Intarcia Names Top Commercial Expert Michael Williams As COO; Will Chair Commercial Committee And Lead ITCA 650 Launch In U.S. 3Intarcia Names Top Commercial Expert Michael Williams As COO; Will Chair Commercial Committee And Lead ITCA 650 Launch In U.S. 4
(Date:5/4/2015)... In a continuing effort to remain ... Per Wickstrom, the founder of Choices Recovery in South ... “Salute to the Oscars” celebration held on February ... floor of the luxurious Beverly Hilton Hotel. , ... sustainable product placement in TV and film, this daylong ...
(Date:5/4/2015)... May 04, 2015 McNeil & ... announces the expansion of coverage for its Emergency ... provider of industry-tailored insurance and proactive risk management to ... we are dedicated to providing our customers with unparalleled ... many evolving needs. We are excited to launch over ...
(Date:5/4/2015)... Orange, NJ (PRWEB) May 04, 2015 ... non-profit organization devoted exclusively to funding innovative lymphoma research ... of education programs, outreach initiatives and patient services – ... at the historic Mayfair Farms in West Orange, NJ ... raised nearly $500,000 for innovative research programs through LRF. ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 METTLER ... The Importance of Data Integrity in a GXP ... as guest presenter. This webinar will be presented ... GMT). , Data integrity is a critical component ... to regulatory agencies. However, in recent years an ...
(Date:5/4/2015)... Seattle, WA (PRWEB) May 04, 2015 ... of a collaboration to facilitate development of NM108, a ... disorders that lead to blindness, including Diabetic Retinopathy. ... formulation platform developed by EyeCRO, which can deliver drugs ... a topical eyedrop. , Under the terms of ...
Breaking Medicine News(10 mins):Health News:Per Wickstrom Interviews TV and Film Star Carolyn Hennesy About Substance Abuse and Treatment 2Health News:Insurance Leader McNeil & Company Expands Coverage for Emergency Services Insurance Program (ESIP), Launches Enhancements to Property and Casualty Insurance Package 2Health News:Insurance Leader McNeil & Company Expands Coverage for Emergency Services Insurance Program (ESIP), Launches Enhancements to Property and Casualty Insurance Package 3Health News:Lymphoma Research Foundation Set to Host Annual Ace Lymphoma Luncheon at Mayfair Farms in West Orange, NJ 2Health News:METTLER TOLEDO Announces Live Webinar on the Importance of Data Integrity in a GXP Regulated Laboratory 2Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 2Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 3
... it is commonly thought that men with low IQs ... sexual deviance, new research has found the men may ... education previously taken. , A team of North ... without an intellectual disability and a history of sexual ...
... Following a spate of accidental infant,suffocation deaths in Detroit ... awarded a $25,000 grant to support a community-based,initiative called ... safe place for newborns to sleep. The grant is ... is to improve the health status,of all Michigan residents, ...
... and reduce risk of ... medication errors, ... to continually improve patient safety,and staff efficiency, Omnicell, Inc. (Nasdaq: ... and Grant Regional Health,Center, a leading healthcare provider, today announced the ...
... N.C., Oct. 16 As the pace ... their market research,groups to keep up. Effective ... by using customers, markets and competitors as,reference ... according to,research from benchmarking leader Best Practices, ...
... Herley Industries,Inc. (Nasdaq: HRLY ) announced today ... been awarded a contract valued at,approximately $5 million ... produce high power amplifiers for EDO,s CVRJ (CREW,Vehicle ... CEO, commented, "EDO has recently,announced awards with options ...
... vomiting, researchers say , TUESDAY, Oct. 16 (HealthDay News) ... sushi and sashimi -- increases the risk of infection ... severe stomach and intestinal problems such as diarrhea, cramping, ... emergency department, say two cases studies by Japanese researchers. ...
Cached Medicine News:Health News:'Corrective' sex education may make sexual offenders more dangerous 2Health News:Blue Cross Blue Shield of Michigan Awards Grant to Reduce Accidental Infant Suffocations in Wayne County 2Health News:Grant Regional Health Center Increases Patient Safety and Pharmacy Efficiency with Omnicell Medication Use Systems 2Health News:Grant Regional Health Center Increases Patient Safety and Pharmacy Efficiency with Omnicell Medication Use Systems 3Health News:Creating an Effective Market Research Group to Generate High-Impact Business Results 2Health News:Herley Industries, Inc. Receives a $5 Million Award from EDO for Electronic Components for IEDs 2Health News:Raw Seafood Poses Digestive Risks 2
... Eppendorf Multipurpose Centrifuges feature ... accommodate a variety of rotors ... are three centrifuges in one: ... centrifuge for cell harvesting; a ...
Inquire...
Inquire...
Inquire...
Medicine Products: